Category: DEVICE - Page 6 - Start Medical Product Development

Drug-coated balloons could offer an alternative to permanent heart stents for some patients

October 15, 2026

Thousands of heart patients could be treated without having a metal stent permanently implanted in their arteries—according to research from the University of East Anglia (UEA). A major analysis of more than 7,800 patients found that a newer treatment using drug-coated balloons performed just as well as conventional stents at preventing heart attacks and cardiovascular deaths.

Mixed beam measurement method could help make ion cancer therapy more precise

October 14, 2026

In ion beam therapy, atomic nuclei are accelerated to high energies in a particle accelerator, for example, a synchrotron, and precisely directed at a tumor. There, they damage cancer cells and destroy tumor tissue. This technique is now used at several specialized medical facilities around the world, including MedAustron in Wiener Neustadt, Austria.

FDA approves Providence Medical’s CORUS PCSS 3D-T spinal device

October 14, 2026

CORUS incorporates integrated screw fixation as a nonsegmental posterior instrumentation tool.

FDA APPROVES GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS FOR EXPANDED USE IN FEVAR AND BEVAR

October 14, 2026

FLAGSTAFF, Ariz., Oct. 14, 2026 /PRNewswire/ — W. L. Gore & Associates’ medical business (Gore) today announced U.S. Food and Drug Administration approval of an expanded indication for the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) for use in fenestrated and branched endovascular aortic repair (FEVAR and BEVAR).

Maverix Medical Expands the Narwhal™ Cryo Portfolio with FDA Clearance of the Narwhal Pro

October 14, 2026

MENLO PARK, Calif., Oct. 14, 2026/PRNewswire/ — Maverix Medical, a company focused on revolutionizing the diagnosis and treatment of lung cancer, has augmented its console-free cryoprobe portfolio. Today the company announced that the U.S. Food and Drug Administration granted 510(k) clearance on September 2, 2026, to the Maverix Narwhal™ Pro Cryo System, the second of two flexible cryoprobes built on the same cartridge-powered architecture.

Trial Demonstrates Feasibility of At-Home Subcutaneous Diuretic Therapy for Heart Failure-Associated Edema

October 14, 2026

BURLINGTON, Mass., Oct. 14, 2026 /PRNewswire/ — SQ Innovation today announced that results of the SUBCUT HF II trial of its product Lasix® ONYU have been published in the Journal of the American College of Cardiology (JACC)1, one of the leading peer-reviewed journals in cardiovascular medicine.

Targeted radioactive therapy may help delay spread of recurrent prostate cancer

October 13, 2026

Adding the targeted radioactive drug 177Lu-PNT2002 to stereotactic body radiation therapy, or SBRT, may help keep recurrent prostate cancer under control longer than SBRT alone, according to new research led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

DEVICE

Drug-coated balloons could offer an alternative to permanent heart stents for some patients

Mixed beam measurement method could help make ion cancer therapy more precise

FDA approves Providence Medical’s CORUS PCSS 3D-T spinal device

FDA APPROVES GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS FOR EXPANDED USE IN FEVAR AND BEVAR

Maverix Medical Expands the Narwhal™ Cryo Portfolio with FDA Clearance of the Narwhal Pro

Trial Demonstrates Feasibility of At-Home Subcutaneous Diuretic Therapy for Heart Failure-Associated Edema

Targeted radioactive therapy may help delay spread of recurrent prostate cancer

Blink-powered glasses could keep an eye on health

FDA grants 510(k) clearance for Urolution Medical’s OpenFlo catheter

Tiny robots speed medicine through body to the heart